Welcome to our dedicated page for Biorestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on Biorestorative Therapies stock.
BioRestorative Therapies develops regenerative medicine products using cell and tissue protocols, primarily involving adult stem cells. News about BRTX centers on BRTX-100, its autologous hypoxic-cultured mesenchymal stem cell therapy for chronic lumbar disc disease, including clinical trial updates, safety and efficacy data presentations, and regulatory interactions tied to the program.
The company also reports developments involving its ThermoStem metabolic program and its commercial BioCosmeceutical platform. Recurring updates include scientific conference presentations, collaborations supporting BioCosmeceutical commercialization, capital actions, shareholder communications, and business updates related to development spending and platform expansion.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BioRestorative Therapies, Inc. (BRTX), a clinical-stage company focused on stem cell therapies, has completed enrollment for the safety run-in of its Phase 2 clinical study of BRTX-100. This innovative treatment aims to address chronic lumbar disc disease (cLDD) by targeting areas with low blood flow. The study is randomized and double-blinded, involving up to 99 patients at 15 U.S. clinical sites. CEO Lance Alstodt highlighted the milestone, stating that positive safety results would enable broader enrollment and further development of BRTX-100 across other medical applications. The company aims to leverage this platform for expedited regulatory pathways. Initial clinical data is expected to be released in the second half of 2023.
BioRestorative Therapies (BRTX) has engaged Bruder Consulting & Venture Group to help expand the clinical indication pipeline for BRTX-100, its lead candidate targeting chronic lumbar disc disease (cLDD). Currently in a Phase 2 trial, BRTX-100 is a novel cell-based therapy aimed at areas with limited blood flow. The randomized, double-blinded trial involves 99 patients across 15 sites in the U.S. with a focus on safety and efficacy. BCVG's expertise in regulatory processes will support BioRestorative in obtaining FDA approval for new clinical applications of BRTX-100.
BioRestorative Therapies, Inc. (BRTX) announced its participation in the Roth 35th Annual Conference from March 12-14, 2023, at The Ritz Carlton, Laguna Niguel in Dana Point, California. CEO Lance Alstodt will be available for one-on-one meetings and provide updates on the company's pipeline, including the ongoing Phase 2 clinical trial for BRTX-100, targeting chronic lumbar disc disease. BioRestorative focuses on cell-based therapies, emphasizing its lead product for disc disorders and a metabolic program aimed at obesity. More information about the conference can be found on their official website.
BioRestorative Therapies (BRTX) announced a notice of allowance for a patent on its ThermoStem® program, which targets obesity and metabolic disorders, including type 2 diabetes. Issued on February 24, 2023, this marks the third patent in the ThermoStem family. The new patent covers implantable three-dimensional scaffolds and brown adipocytes derived from human stem cells. CEO Lance Alstodt stated this advancement strengthens the company's technology and opens doors for collaborations. BioRestorative also develops a disc/spine therapy using autologous stem cells.